Recent Pfizer Press Releases

  • 6/6/18 8:00 am EDT

    Approximately 25% of new funding to be dedicated to neuroscience

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle. In addition to increased funding, Pfizer will extend its leadership as a venture capital investor with an expanded team that leverages expertise across venture capital investing, business development, drug discovery and clinical developmentmore...
  • 6/4/18 5:37 pm EDT

    Overall Survival Data from Head-to-Head Phase 3 ARCHER 1050 Trial Comparing Dacomitinib to Gefitinib Presented at ASCO 2018

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) data from the ARCHER 1050 trial evaluating dacomitinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations compared to gefitinib. The trial showed a median OS of 34.1 months for patients receiving dacomitinib (95% CI: 29.5, 37.7), representing a more than seven-month improvement compared to 26.8more...
  • 6/1/18 7:30 am EDT

    TRAZIMERA, a potential biosimilar to Herceptin ® (trastuzumab), is Pfizer’s first therapeutic oncology biosimilar to undergo regulatory review in Europe

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for TRAZIMERA™, a potential biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.1 ”Pfizer ismore...
  • 5/30/18 3:52 pm EDT

    XELJANZ, an Oral Therapy, is the First and Only JAK Inhibitor Approved in the U.S. for This Patient Population

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis (UC).1 “Ulcerative colitis is a chronic inflammatory bowel disease that can significantly impact the livesmore...
  • 5/30/18 7:00 am EDT

    This Second Round of Funding Builds on Initial $6.7 Million Grant Program

    NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation announced today a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for women and men at the same time children are routinely vaccinated. These new grants build on The Pfizer Foundation’s existing grant program by providing a second round of funding to international nongovernmental organizations (INGOs) in five African countries wheremore...
  • 5/29/18 8:00 am EDT

    XALKORI is the First Tyrosine Kinase Inhibitor to Receive Breakthrough Designation for the Treatment of Patients with Previously-treated Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations

    Additional Breakthrough Therapy Designation for the Treatment of Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma that is ALK-positive

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for XALKORI® (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA also granted Breakthrough Therapy designation for XALKORI for the treatment of patients with relapsed ormore...
  • 5/23/18 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that tafamidis received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with transthyretin cardiomyopathy, a rare, fatal, and underdiagnosed condition associated with progressive heart failure.1,2 This decision is supported by topline results from the tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, in which tafamidismore...
  • 5/22/18 1:30 pm EDT

    Study Finds Prevnar 13 was Associated With Reduced Risk of Hospitalization From Vaccine-Type Community-Acquired Pneumonia in Older Adults 1

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that results from a study analyzing real-world effectiveness data found that Prevnar 13® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 Protein]) reduced the risk of hospitalization from vaccine-type pneumococcal community-acquired pneumonia (CAP) by 73% (95% CI: 12.8−91.5%) in adults aged 65 and older.1 Importantly, Prevnar 13 (PCV13) worked under real-world conditions where peoplemore...
  • 5/22/18 8:00 am EDT

    RSV affects 33 million children globally and leads to approximately 120,000 childhood deaths every year 1

    In the United States approximately 177,000 older adults are hospitalized annually because of RSV 2

    The clinical program aims to develop a vaccine for populations at highest risk of infection: infants through maternal immunization, and older adults through direct vaccination

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults. The highest risk of severe outcome from RSV occurs in the first months of life.3 “A successful RSV vaccine has been an elusive goal for themore...
  • 5/17/18 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today positive top-line results of a Phase 3 study examining the use of LYRICA® (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age. Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpointmore...